XML 48 R37.htm IDEA: XBRL DOCUMENT v3.22.2
Business Combination -Purchase Consideration (Details) - USD ($)
$ in Thousands
3 Months Ended
May 24, 2022
Jun. 30, 2022
Business Acquisition [Line Items]    
Consideration related to Antares closing indebtedness settled by Halozyme $ 19,700  
Share-based compensation expense   $ 8,700
Antares Pharma, Inc    
Business Acquisition [Line Items]    
Cash consideration for Antares shares outstanding as of May 24, 2022 956,886  
Consideration for Antares equity compensation awards 45,828  
Consideration for seller transaction costs paid by Halozyme 22,906  
Consideration related to Antares closing indebtedness settled by Halozyme 19,683  
Cash consideration related to cash bonus awards paid by Halozyme 365  
Consideration transferred 1,045,668  
Antares Pharma, Inc | Equity Compensation Awards, Vested    
Business Acquisition [Line Items]    
Consideration for Antares equity compensation awards 32,200  
Antares Pharma, Inc | Equity Compensation Award, Unvested    
Business Acquisition [Line Items]    
Consideration for Antares equity compensation awards $ 13,600